Apollomics, Inc. (APLM) Stock Price & Analysis
Apollomics, Inc. (APLM) — MoonshotScore 34/100 (Weak band), calculated Nov 22, 2026. Price $15.54 (-6.92%), as of the Nov 20, 2026 trading session; market cap $45.3M.
Educational signal · not a buy or sell recommendation · How to read this
Apollomics, Inc. · APLM · NASDAQ
Apollomics, Inc. is a biotechnology company focused on the discovery and development of oncology therapies. The company aims to address unmet medical needs in California, China, and Australia.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Apollomics (APLM)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite growth, but a fragile balance sheet and an expensive valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Average; Financial Safety: Fragile; Valuation: Rich; Growth Durability: Compounding; Momentum: Rising.
- quarterly revenue $9M (Q2 FY2025, quarter ended Jun 30, 2025)
- EPS beat 1 of the last 3 reports
Holding back: balance-sheet strain, a rich price
Helping: durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 33 | Weak | |
| 33 | Weak | |
| 33 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak |
The score was 34 in the stored Nov 21, 2026 snapshot and remains 34 in the current publication computed Nov 22, 2026 (0); the largest pillar moves were Momentum +3 and Valuation -2; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $15.54 | |
| Change on the day | -6.92% | |
| Market capitalisation | $45.3M | — |
| Shares traded on the day | 4.1K |
Price & events
Other perspectives
Council score for Apollomics (APLM): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
3 lenses, 3 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 21, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company more favourably than the MoonshotScore does: Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 22, 2026, except a card that shows its own read date.
What is Apollomics (APLM), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Apollomics, Inc. (APLM) is listed on NASDAQ. It employs 14 people. In Q2 FY2025 it reported revenue of $9M and net income of -$13M. The market values it at $45.3M.
What do the latest results show for Apollomics (APLM)?
Short answer · as of
The most recent reported quarter, Q2 FY2025, carried revenue of $9M. Against analyst estimates the company has EPS beat 1 of the last 3 reports.
Quarterly income statement — 1 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2025 | $9M | -$13M | -$11.37 (diluted) |
What are the financial strengths and risks for Apollomics (APLM)?
Short answer · as of
The MoonshotScore pillars rate durable growth as strengths. What is holding it back is balance-sheet strain, a rich price. The distress and quality screens read Piotroski F 0. Trailing ratios: ROA -67.1% · current ratio 0.15.
What should you watch next at Apollomics (APLM)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $13.26M · EPS -122.00 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- The newest quarter held here (Q2 FY2025) was filed Dec 22, 2025 — 10 months ago.
Checked against the records this page reads, on the dates shown above.
How does Apollomics compare with its peers?
Short answer
Apollomics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.09 Nov 20, 2026 | $462M | 92 5-pillar Nov 22, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 22, 2026 | |
| $2.90 Nov 20, 2026 | $245M | 90 5-pillar Nov 22, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 87 5-pillar Nov 22, 2026 | |
| $15.47 Nov 20, 2026 | $83.3M | 82 5-pillar Nov 22, 2026 | |
| $10.92 Nov 20, 2026 | $99.3M | 82 5-pillar Nov 22, 2026 | |
| $3.57 Nov 20, 2026 | $155M | 72 5-pillar Nov 22, 2026 | |
| $1.84 Nov 20, 2026 | $174M | 70 5-pillar Nov 22, 2026 | |
| $11.54 Nov 20, 2026 | $817M | 69 5-pillar Nov 22, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 22, 2026 | |
| $7.98 Nov 20, 2026 | $780M | 64 5-pillar Nov 22, 2026 | |
| $30.43 Nov 20, 2026 | $1.02B | 64 5-pillar Nov 22, 2026 | |
| Apollomics (APLM) — this page | $15.54 | $45.3M | 34 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $13.26M
- EPS estimate
- $-122.00
Measured against a quoted price of $15.54 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 15, 2026
- Transactions
- 52
- Identified insiders
- 9
- Purchases
- 5
- Sales
- 0
- Other transactions
- 47
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held APLM in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported APLM in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Apollomics (APLM)?
Investor Questions: APLM Stock
These answers are editorial: 1 of these 9 answers is drawn from the APLM research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for APLM?
APLM carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Apollomics, Inc. is a biotechnology company focused on the discovery and development of oncology therapies.
Is APLM a good stock to buy?
Stock Expert AI does not rate APLM buy, sell or hold. Apollomics, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the APLM stock price today?
The last price recorded for Apollomics, Inc. (APLM), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for APLM?
The main risks for Apollomics, Inc. include clinical trial failures for its drug candidates, regulatory delays or rejections, competition from larger pharmaceutical companies with greater resources, dependence on external funding to support its operations, and patent expirations.
What are the key factors to evaluate for APLM?
Apollomics, Inc. (APLM) holds a MoonshotScore in the low range. Establishing a presence in key markets like China and Japan could drive long-term growth for Apollomics. Not financial advice.
How frequently does APLM data refresh on this page?
APLM's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven APLM's recent stock price performance?
Apollomics, Inc. (APLM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline of oncology therapies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider APLM overvalued or undervalued right now?
Apollomics, Inc. (APLM) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of APLM?
Fractional-share availability for Apollomics, Inc. (APLM) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 18 figures on this page — 10 from Financial Modeling Prep (FMP), 6 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com